Bharat Immunologicals & Biologicals Corporation Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹23
- Today's High:
- ₹25.4
- Open Price:
- ₹25.39
- 52W Low:
- ₹20.5
- 52W High:
- ₹51.8
- Prev. Close:
- ₹25.31
- Volume:
- 80446
Company Statistics
- Market Cap.:
- ₹921.89 million
- Book Value:
- 4.822
- Revenue TTM:
- ₹789.90 million
- Operating Margin TTM:
- -5.24%
- Gross Profit TTM:
- ₹108.74 million
- Profit Margin:
- -9.54%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Bharat Immunologicals & Biologicals Corporation Limited had its IPO on under the ticker symbol 524663.
The company operates in the Other sector and Other industry. Bharat Immunologicals & Biologicals Corporation Limited has a staff strength of 0 employees.
Stock update
Shares of Bharat Immunologicals & Biologicals Corporation Limited opened at ₹25.39 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹23 - ₹25.4, and closed at ₹23.76.
This is a -6.12% slip from the previous day's closing price.
A total volume of 80,446 shares were traded at the close of the day’s session.
In the last one week, shares of Bharat Immunologicals & Biologicals Corporation Limited have slipped by -3.61%.
Bharat Immunologicals & Biologicals Corporation Limited's Key Ratios
Bharat Immunologicals & Biologicals Corporation Limited has a market cap of ₹921.89 million, indicating a price to book ratio of 5.9621 and a price to sales ratio of 1.1325.
In the last 12-months Bharat Immunologicals & Biologicals Corporation Limited’s revenue was ₹789.90 million with a gross profit of ₹108.74 million and an EBITDA of ₹0. The EBITDA ratio measures Bharat Immunologicals & Biologicals Corporation Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bharat Immunologicals & Biologicals Corporation Limited’s operating margin was -5.24% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Bharat Immunologicals & Biologicals Corporation Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 173.6%.
Bharat Immunologicals & Biologicals Corporation Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹-1.739 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bharat Immunologicals & Biologicals Corporation Limited’s profitability.
Bharat Immunologicals & Biologicals Corporation Limited stock is trading at a EV to sales ratio of 1.3793 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 1.1325.
Bharat Immunologicals & Biologicals Corporation Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹2.11 billion
- Total Liabilities
- ₹1.07 billion
- Operating Cash Flow
- ₹0.00
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Bharat Immunologicals & Biologicals Corporation Limited ended 2024 with ₹2.11 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.11 billion while shareholder equity stood at ₹972.73 million.
Bharat Immunologicals & Biologicals Corporation Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.07 billion in other current liabilities, 431800000.00 in common stock, ₹540.93 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹79.68 million and cash and short-term investments were ₹81.45 million. The company’s total short-term debt was ₹801,407,000 while long-term debt stood at ₹0.
Bharat Immunologicals & Biologicals Corporation Limited’s total current assets stands at ₹581.58 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹277.77 million compared to accounts payable of ₹0 and inventory worth ₹82.31 million.
In 2024, Bharat Immunologicals & Biologicals Corporation Limited's operating cash flow was ₹0.00 while its capital expenditure stood at ₹0.
Comparatively, Bharat Immunologicals & Biologicals Corporation Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹23.76
- 52-Week High
- ₹51.8
- 52-Week Low
- ₹20.5
- Analyst Target Price
- ₹
Bharat Immunologicals & Biologicals Corporation Limited stock is currently trading at ₹23.76 per share. It touched a 52-week high of ₹51.8 and a 52-week low of ₹51.8. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹23.04 and 200-day moving average was ₹25.16 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5925.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Bharat Immunologicals & Biologicals Corporation Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, ready to use therapeutic food, low calorie sweetener tablets, etc. The company was founded in 1989 and is based in Bulandshahr, India.